GT Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTBP research report →
About the company
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
- CEO
- Michael Martin Breen
- IPO
- 2018
- Employees
- 1
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $5.01M
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 1.88
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -901.32%
- ROIC
- -204.98%
- Revenue
- $0 · 0.00%
- Net Income
- $-28,354,000 · -115.42%
- EPS
- $-6.25 · 9.94%
- Op Income
- $-12,422,000
- FCF YoY
- -0.08%
- 52W High
- $2.86
- 52W Low
- $0.26
- 50D MA
- $0.41
- 200D MA
- $0.57
- Beta
- 0.86
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on GTBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 25 | Mun-Gavin David C. | other | 31,250 |
| Sep 4, 25 | Breen Michael Martin | other | 100,000 |
| Sep 4, 25 | URBAN ALAN LOUIS | other | 50,000 |
| Sep 4, 25 | CASAMENTO CHARLES J | other | 62,500 |
| Sep 4, 25 | Kramer Hilary | other | 31,250 |
| Jun 10, 25 | Mun-Gavin David C. | other | 0 |
| May 7, 25 | Kramer Hilary | other | 0 |
| May 8, 25 | Ritter Andrew J | other | 0 |
| Oct 17, 24 | URBAN ALAN LOUIS | other | 23,335 |
| Jun 3, 24 | URBAN ALAN LOUIS | other | 0 |
Our GTBP coverage
Recent articles, reports, and earnings notes.
No research on GTBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GTBP report →Similar companies
Peers in the same neighborhood.